|
C2ORF76 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.82389999956601E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.564540E-04 |
| Normal-vs-Stage2 |
5.560400E-03 |
| Normal-vs-Stage3 |
2.06189999962803E-07 |
| Normal-vs-Stage4 |
3.80310005709816E-10 |
| Stage1-vs-Stage2 |
8.617200E-01 |
| Stage1-vs-Stage3 |
1.144340E-02 |
| Stage1-vs-Stage4 |
5.10090000016561E-07 |
| Stage2-vs-Stage3 |
1.402180E-01 |
| Stage2-vs-Stage4 |
8.058200E-03 |
| Stage3-vs-Stage4 |
6.084100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.64189999999287E-07 |
| Normal-vs-AfricanAmerican |
1.148290E-02 |
| Normal-vs-Asian |
5.018000E-03 |
| Caucasian-vs-AfricanAmerican |
7.351800E-01 |
| Caucasian-vs-Asian |
3.143800E-01 |
| AfricanAmerican-vs-Asian |
7.328000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.53209999984728E-07 |
| Normal-vs-Female |
1.52571999999518E-05 |
| Male-vs-Female |
3.060600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.165620E-04 |
| Normal-vs-Age(41-60Yrs) |
1.37420000001498E-06 |
| Normal-vs-Age(61-80Yrs) |
1.02260000001131E-06 |
| Normal-vs-Age(81-100Yrs) |
4.591600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.836610E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.788200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.480000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.791400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.116200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.053800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.102500E-02 |
| Classical-VS-Follicular |
1.235790E-03 |
| Classical-VS-Other |
8.770600E-01 |
| Classical-VS-Normal |
1.37280000034323E-07 |
| Tall-VS-Follicular |
1.043000E-04 |
| Tall-VS-Other |
2.540800E-01 |
| Tall-VS-Normal |
1.51920000002193E-06 |
| Follicular-VS-Other |
3.627800E-01 |
| Follicular-VS-Normal |
1.265760E-01 |
| Other-VS-Normal |
8.159700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.94590000000195E-05 |
| Normal-vs-N1 |
1.032610E-04 |
| N0-vs-N1 |
4.688600E-01 |
|
|
